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A B S T R A C T
Background: The Association of Pharmacists in Belgium (APB) and local pharmacy associations launched a pilot
project in collaboration with research teams from three Belgian universities to study the impact and im-
plementation-related issues of a medication review (MR) service type 2a in Belgian community pharmacies.
Objective: The aim of this paper is to describe the implementation process of the MR service and to present the
implementation evaluation of the pilot study (testing stage).
Methods: The pilot project was a prospective observational study using mixed methods. The implementation
evaluation was based on the RE-AIM model and the framework for the implementation of services in pharmacy
(FISpH). Collected implementation outcomes were classified into four dimensions: reach, adoption, im-
plementation and intent of maintenance.
Results: During the testing stage, 80 pharmacies participated in the study, but 25 dropped out (31%), mainly
because of a reported lack of time (adoption). The 55 remaining pharmacies included 457 patients. Recruiting
patients into the service was challenging for pharmacists as 48.5% of patients refused the pharmacists' proposal
(reach). Internal organizational factors were major barriers for pharmacists, followed by the lack of adoption by
the pharmacy team. Large pharmacies in which pharmacy owner led the project were observed to be more
proactive in implementing the MR service by integrating organizational strategies to assist the implementation
process (implementation). Interviewed pharmacists perceived this new service as a professionally satisfying
activity. Among participating pharmacists, 92.5% found this service feasible in practice, but believed it required
adapted resources to reorganize the internal pharmacy workload, additional support, such as broad-based media
campaigns to increase physicians' and patients’ awareness and attitudes towards the service, and modified
software (maintenance).
Conclusions: The medication review service was implemented in 68% of participating pilot Belgian community
pharmacies but would require adapted resources and supports for larger scale implementation.
Introduction
In Belgium, the concept of pharmaceutical care was introduced in
the modified Royal Decree of the 1st of May 2006 and then defined
more in details in 2009 by the good pharmaceutical practice guidelines.
In the latter, pharmacists are recognized as pharmaceutical caregivers
responsible for continuously improving drug use and maintaining or
improving patient quality of life, including prevention, identification
and resolution of DRPs.1,2 The two related royal decrees were co-
ordinated on the 10th of May 2015 with the law regarding the exercise
of health care professions.3 These changes were a first step in the
evolution of the pharmacist's role, which became a patient-centred
approach. Since April 2010, a new remuneration system has been im-
plemented in Belgium that includes a base fee covering basic
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pharmaceutical care delivered by pharmacists, fixed at 4.27 EUR per
prescribed drug. Specific pharmacy services are starting to be devel-
oped in practice. Remuneration of pharmacists for these services is
supported by the National Institute for Health and Disability Insurance
and, therefore, are free of charge for patients.4 The first Belgian re-
munerated service, the new medicines service for asthma patients with
a first prescription for a corticosteroid inhaler treatment, was in-
troduced in October 2013. Despite the availability of this new re-
munerated service, it appeared that the service was poorly provided in
practice and that the allocated budget by the authorities was under-
employed. The fidelity assessment also revealed poor communication
around this new service and a lack of engagement from pharmacists,
other health care professionals, and patients.5
Implementation quality of new pharmaceutical services has often
been poorly studied, and their impact on professional practices has
remained limited around the world.6 In the field of health care, it is
important to differentiate the evaluation of the intervention effective-
ness (related to patient outcomes) and its implementation analysis in
practice.7 Implementation science is defined as “the study of methods to
promote the adoption and the integration of evidence-based practices,
interventions and policies into routine health care and public health
settings.”8 Therefore, implementation science focuses on processes,
impact (including barriers, facilitators, strategies and evaluations), and
outcomes of implementation of a new service in practice.9 Im-
plementation science has increased in the past few years and im-
plementation studies of new pharmaceutical services have begun to
emerge in the literature and started to become recognized as essential
to ensure their good delivery and, therefore, their effectiveness.9,10
Poor implementation of new pharmaceutical services is not confined to
Belgium and remains a worldwide issue, mostly due to lack of time, lack
of resources and lack of interprofessional collaboration.9,11 However,
other examples in the literature show that the implementation of
community pharmacy services in practice is feasible if potential influ-
encing factors are considered and anticipated on beforehand and im-
plementation strategies are used.12,13
In Belgium, the legally established concept of pharmaceutical care
includes the “prevention, identification and resolution of drug-related
problems with other health care professionals,” implying the possibility
of a structured evaluation of the patient's medicines, called medication
review (MR).14 The MR service is being explored as a possible next step
in the development of pharmaceutical care in Belgium, as it is a pro-
mising service to improve medication adherence and has shown a po-
sitive impact on patient clinical outcomes and drug-related problems
(DRPs).15,16 In some countries such as Switzerland, Australia, New
Zealand, Canada, United Kingdom (UK) or United States of America
(USA), a specific remuneration for this type of service exists.17
The new medicines service for Belgian asthma patients was laun-
ched without a testing phase or implementation consideration, re-
sulting in poor implementation. Considering this implementation
challenge, the Association of Pharmacists in Belgium (“Association
Pharmaceutique Belge” - APB) decided to launch a pilot project in
collaboration with local associations of pharmacists and with research
teams from three universities to study the effectiveness of a MR service
in Belgian community pharmacies and to investigate issues related to
the implementation of this service. This pilot project was aligned as a
hybrid type 2 design, as the Impact of a Medication use EvaluatioN by
the cOmmunity pharmacist (SIMENON study) in elderly polymedicated
patients and its implementation in practice were evaluated together.18
The implementation evaluation was considered a secondary objective
in order to collect data and develop strategies for future national im-
plementation. The objective of this paper is to describe the im-
plementation process of the MR service and to present the im-
plementation evaluation of the pilot study (testing stage).
Methods
Description of the service
The pharmaceutical care network in Europe defined MR as “an
evaluation of a patient‘s medicines with the aim of optimizing medi-
cines use and improving health outcomes. This entails detecting drug-
related problems and recommending interventions.” The tested service
was a MR of a “type 2a” level. The “type 2a” combines the medication
history review with an interview with the patient and is described as an
intermediate MR as it does not include access to medical data.14 This
level was chosen because the patient interview was seen as an essential
part of the project. Due to the specific setting in Belgium, a level 3MR,
in which clinical information is incorporated, was not feasible. Belgian
community pharmacies do not yet have access and are not experienced
in interpreting lab values. Furthermore, interprofessional collaboration
is in their infancy, which complicates the exchange of this type of in-
formation. The feasibility study confirmed that the medication review
type 2a was already considered innovative and challenging for the
participating pharmacists. Therefore, the APB foresees a step-up ap-
proach for the implementation of MR in Belgium, in which this medi-
cation review type 2a is a first essential step.
The tested MR service included 6 steps: (1) patient inclusion (at the
counter); (2) interview preparation based on the medication history,
including searching for potential drug-drug interactions, side effects
and available education materials for the drugs used by the patient; (3)
first interview with the patient, including patient data collection (at the
pharmacy in a private counselling area or at home); (4) pharma-
cotherapeutic analysis, including detection of DRPs, identification of
needed interventions and treatment plan preparation; (5) second in-
terview with the patient to discuss the proposed interventions and
provide the treatment plan (in the pharmacy, at the counter or in a
private area, or at home); and (6) follow-up interview (at the counter
during the next patient visit to the pharmacy). Contact with the pa-
tient's physician was recommended for steps 2, 4 and 5 but was not
compulsory.
It is important to note that for the pilot study, pharmacists were
asked to include 12 patients during 2 defined half-days. The target
sample of 12 patients per pharmacy was based on a sample size cal-
culation for the effectiveness study. During the defined inclusion days,
pharmacists had to propose the MR service to all eligible patients.
Patients were eligible if they were ≥70 years, using ≥5 chronic
medicines and living in an ambulatory setting. The full protocol of the
project, including the development of this service and its description,
the description of the educational program and the protocol of the
impact evaluation, is described elsewhere.19
Description of the framework used to describe the implementation process
The implementation strategies developed for the pilot project are
described through the defined stages of the framework for the im-
plementation of services in pharmacy (FISpH).9 The framework states
that implementation is a complex multi-stage process involving an in-
novation (in this case the MR service to be implemented), a multi-level
context (individuals, pharmacy(s), local setting and system), influenced
by a range of factors, strategies, and evaluations (Fig. 1). This frame-
work was chosen because it was based on a literature review of existing
and largely used validated frameworks and adapted for the community
pharmacy setting. For this study, we described the development of the
intervention, the exploration, the preparation and the testing stages
corresponding to the pilot study.
Assessment of implementation during the testing stage
Study design
A prospective observational study using a mixed method approach
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(quantitative and qualitative analyses) was undertaken.
Participants
All pharmacies in Belgium were eligible to participate in the pilot
project. For the qualitative analysis, community pharmacists partici-
pating in this pilot project were contacted by email and invited to
participate to a focus group on a voluntary basis.
Collected outcomes
The implementation evaluation of the testing stage was based on the
RE-AIM model. This implementation evaluation model defines five di-
mensions: reach, adoption, effectiveness, implementation and main-
tenance.20 These dimensions, with the exception of the effectiveness,
were evaluated with both quantitative and qualitative research
methods. Quantitative data were defined to reflect as close as possible
the RE-AIM dimensions in a pilot project context and qualitative data
were defined to explore potential influencing factors of these dimen-
sions. Collected outcomes were completed and enriched with the out-
comes of the evaluation model related to the FISpH.7 For this project,
reach rate and maintenance were not appropriate as it was a pilot study
intending to explore the impact and implementation of the MR service
in Belgian community pharmacies. Outcomes were therefore adapted in
measuring an acceptance rate instead of a reach rate and in exploring
potential influencing factors for a future national implementation.
Collected outcomes are described in Table 1.
Data collection
Quantitative data were collected through (1) the web platform de-
signed for this pilot project, where pharmacists recorded the informa-
tion collected during the patient interview; (2) an online questionnaire
sent to all pharmacists in March 2017 to evaluate the “patient re-
sponsiveness” score21; and (3) an online survey sent to all participating
pharmacists at the end of the project (June 2017). The online ques-
tionnaire for patient responsiveness used the scale developed by
Moullin et al. The “patient responsiveness” scale was developed to be
administered to pharmacists and represent their perspective based on
two factors “participation and enthusiasm” of patients. The ques-
tionnaire contains 12 questions with a 5-point Likert scale format,
where 1= never; 2= rarely; 3= sometimes; 4= often; and 5= al-
ways. The scale was evaluated in terms of content validity, acceptability
and internal consistency by Moullin et al.21 In order to avoid missing
data, all questions were mandatory. The end of project survey was used
to collect required outcomes that were not available into the web
platform. Questions were related to socio-demographic information of
participating pharmacists and pharmacies, the number of MR proposals
and refusals, and the pharmacists’ opinions regarding the feasibility of
the service in practice (open-ended and multi-choice questions).
Qualitative data were collected by two investigators (ML and CH)
during semi-structured focus groups with participating pharmacists
between February and April 2017. The interview guides, one for the
focus group and one for drop-out pharmacists, were based on the de-
fined implementation outcomes that were based on the RE-AIM.
Pharmacists who did not include patients during the pilot project were
also contacted and interviewed by phone by the investigators (ML or
CH) to understand the reasons of non-inclusion. At the time of the
study, ML, who conducted the French focus groups, was experienced
with qualitative study and trained CH during the four French focus
groups to conduct the last focus group with Dutch pharmacists.
Additional quantitative and qualitative information given by phar-
macists during phone calls with local coaches of the local pharmacists’
associations was added to the results. All materials (web platform,
survey, patient responsiveness scale and interview guide) were trans-
lated both in French and Dutch. The patient responsiveness scale was
translated following the ISPOR guidelines.22
Analysis of the results
Quantitative data were represented with the median and inter-
quartile range for continuous variables for avoiding interference of
potential outliers and with proportions for discrete variables.
For qualitative analysis, all focus groups were recorded and tran-
scribed verbatim. Each pharmacist received a number in a separate file
which was only available to the research team to ensure anonymity.
The transcriptions were inductively coded by two independent in-
vestigators (ML/CDV for the French focus groups and CH/JM for the
Dutch focus group). Codes defined by the two investigators were mat-
ched together and discordances were discussed. Interviews by phone
were not recorded and directly coded by the interviewer. Codes were
repeated at the end of the interview and confirmed by the interviewed
pharmacist. Finally, codes were grouped into themes and classified
regarding the explored outcomes. ML was trained and experienced in
coding, CH was trained during the study, while CDV and JM had some
knowledge of qualitative methods but both coded text for the first time.
Ethical approval
The study protocol for the implementation evaluation was sub-
mitted to the Erasme Hospital Ethics Committee (ULB, Belgium) in
Fig. 1. Framework for the implementation of services in pharmacy developed by J. Moullin et al.9.
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November 2016 and approved in December 2016 (P2016/529).
Informed consent form was not required for the implementation eva-
luation as collected outcomes were related to pharmacy practice.
Results
Description of the implementation process
Strategies defined during each stage are described in Fig. 2.
During the exploration stage, 102 pharmacists from 72 pharmacies
attended one of the information sessions. Finally, 80 pharmacies par-
ticipated in the pilot project. Some of them had not been present during
the information sessions but were aware of the project through articles
in national and local pharmaceutical magazines. During the preparation
phase, 101 pharmacists, from 64 out of the 80 participating pharma-
cies, participated in the 3-h workshop. All information regarding sup-
porting materials was sent to pharmacists by email and available on the
web platform specifically designed for the pilot project. During the
testing stage, 34 pharmacists participated to the intermediate meeting,
which was the opportunity for them to exchange their experience with
the project and receive initial implementation feedback. The aim of the
implementation feedback was to show the evolution of the im-
plementation process in providing the number of participating phar-
macies, the number of included patients compared to the target of 12
patients per pharmacy, and the number of first and second interviews
delivered.
Assessment of implementation during the testing stage
Eighty pharmacies (36 from the French-speaking part and 44 from
the Dutch-speaking part of Belgium) decided to participate; 25 dropped
out before the end of the study (31%). At the conclusion of the testing
stage, 5 focus groups were organized with 22 pharmacists from 20
participating pharmacies; 4 with French-speaking pharmacists (n= 16
pharmacists) and one with Dutch-speaking pharmacists (n= 6 phar-
macists). Sixteen pharmacists were female, and the median number of
years of experience of interviewed pharmacists was 16.2 years
[IQR=6.0–26.5]. The last focus group with Dutch-speaking pharma-
cists did not generate new information and confirmed data saturation.
All themes and related transcribed sentences of the qualitative analysis
are presented in the Additional file. For the patient responsiveness
scale, 58 pharmacists (24 French and 34 Dutch-speaking pharmacists
out of the 55 pharmacies remaining at the end of the study) answered
the questionnaire. Finally, 67 pharmacists (from 42 pharmacies out of
the 55 remaining pharmacies) completed the web survey sent in June
2017 (Fig. 3).
Reach
Pharmacists, from the 42 pharmacies that completed the web
survey, proposed the program to 887 patients, of which 457 accepted to
participate, resulting in an acceptance rate of 51.5%.
Reasons for refusal
The number of refusals varied across interviewed pharmacists. Some
pharmacists experienced no refusals whereas others reported a high
Table 1
Description of collected outcomes classified into the four dimensions of the RE-AIM.
Dimension Quantitative data Qualitative data
Reach (The absolute number, proportion, and representativeness of
individuals who are willing to participate in a given initiative)
- Acceptance rate = number of included patients divided by
the number of potential patients (= inclusion/
proposals*100)a
- Number of refusals
- Reasons for refusal according to
pharmacists
- MR proposal and reach of the target
population
Adoption (The absolute number, proportion, and representativeness
of settings and intervention agents who are willing to initiate a
program)b
Setting level:
- Characteristics of pharmaciesc
- Number of pharmacy drop-outs during the studyd
Pharmacy level:
- Characteristics of pharmacistse
- Reasons for adopting or rejecting the
service
Implementation (intervention agents' fidelity to the various elements
of an intervention's protocol)f
- Number of included patients per pharmacy
- Number of first interviews delivered to patients
- Number of second interviews deliveredg
- Number of provided interventions regarding the number of
identified DRPs
- Time needed for implementationh
- Patient responsiveness score
- Internal organization and adaptations
to the service process
- Time needed to provide the service
- Facilitators and barriers
- Necessity of educational program and
extra training needed
- Interprofessional contact
Intent of maintenance -Feasibility in practice - Pharmacists' satisfaction with the MR
service
- Prospects and long-term support needed
Notes:
a As this was a pilot study, patient inclusion criteria were defined for the impact study; pharmacists were asked to define two inclusion days to propose the
program to all patients who met the inclusion criteria and to include a maximum of twelve patients per pharmacy. For the implementation evaluation, we decided to
use the number of patients to whom the MR service was proposed to quantify the number of inclusions compared to the number of refusals.
b The number of pharmacists aware of the MR service, needed to calculate the adoption rate (number of pharmacies that participated divided by the number that
were aware of the project), could not be estimated as the information about the project was sent through national and local pharmaceutical magazines.
c Pharmacy language (Dutch or French), number of full-time equivalent pharmacists and technicians per pharmacy, location.
d A pharmacy was considered as a drop out if they did not record any patient in the web platform.
e Gender, age, number of years of experience in the pharmacy, previous experience with MR.
f In this project, fidelity or the extent to which a service is delivered as intended, was described in terms of the pharmacist's adherence to the MR service protocol
(e.g. internal organization/service process; includes inclusion of the target patients as described in the protocol, detection of DRPs and proposition of interventions by
pharmacists, and interprofessional contact), dose of the MR service delivered (number of delivered interviews and interval in between interviews), adaptation of the
service process in practice, and patients' responsiveness to the MR service.
g Second and third interviews were recorded together in the web platform and therefore could not be treated separately.
h Time between the training (educational program) and the first patient included (measured by pharmacy and then presented with the median and interquartile
range).
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• Content definition of the service
• Feasibility study (APB – KU Leuven)
- Feasibility assessment of the study protocol
Development
(March – August 2016)
• Information session to recruit pharmacists 
- Importance and aim of a medication review
- Protocol description
• Communication about the project through 
national and local pharmaceutical magazines
Exploration 
(September – October 2016)
• Workshop session (3 hours):
- « How to conduct a MR » 
- « Communication with physicians and 
patients »




- References / useful websites                      -
e-learning of the Come-on study1
Preparation
(October – November 2016)
•Financial incentive (60€ per included patient)
•Coaches (local pharmacist associations)
•Implementation feedback to pharmacists 
(email)
•Intermediate meeting with pharmacists 
(exchange of experience and feedback)
•Implementation evaluation (web survey, 
focus groups and web platform)
Testing (pilot study)
(December 2016 – June 2017)
Fig. 2. Description of the implementation strategies developed through the development, exploration, preparation and testing stages.
Notes1: This e-learning was developed to support the implementation of a large national project on rational prescribing in nursing homes23 and contains four training
modules: 1) pharmacotherapy of elderly patients, 2) medication review: definition and contribution of each health care professional, 3) how to conduct a medication
review with interprofessional collaboration, and 4) work as a team. The e-learning is available in both French and Dutch.












22 interviewed pharmacists (from 20 
pharmacies, 36.4%)
Interviews:
22 drop outs pharmacists (88.0%)
Web platform:
55 pharmacies (100%)
Online questionnaire (March 2017) -
Patient responsiveness scale : 
58 participating pharmacists
Online survey (June 2017): 
67 pharmacists (from 42 
pharmarcies, 76.4%) 
Fig. 3. Flow chart of the study population for the implementation evaluation.
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level of refusals. Different reasons for refusals were expressed by
pharmacists during focus groups and in the online survey. Patients
mainly refused to participate because they declared that they did not
need the service and were sufficiently autonomous to manage their
treatment (online survey; 40.0% of refusals, n= 172/430).
Lack of time was also expressed as a reason for refusal (25.8%,
n=111/430). During focus groups, some pharmacists declared to have
the feeling that patients, or family members, were not used to this kind
of service and perceived it as an intrusion.
Patients also refused because they thought that it was not the role of
the pharmacist (9.3%, n=40/430). Moreover, pharmacists explained
during focus groups that some concerns regarding the physician were
expressed by patients. Patients had fears about the potential physician's
reaction or because they trusted their physician regarding the pre-
scription. Others refused because the added-value was not recognized
by the physician him/herself.
Lastly, interviewed pharmacists indicated that some patients re-
fused because they already had a medication scheme. Besides, phar-
macists declared that the patients who would benefit the most were
more difficult to convince and often refused to participate.
MR proposal and reach of the target population
Through the proposition of the MR service, pharmacists reported to
have learned that highlighting the benefits of the service such as “de-
tection of an interaction” and “improve your health” before talking
about the study, facilitated the patient inclusion step. On the other
hand, some pharmacists found it easier to present the study before
talking about the benefits as some patients really like to participate in a
study. Pharmacists reconsidered how best to propose the program over
time depending on patients’ reactions. Pharmacists also stated that in-
clusion was easier when the patient was well-known by the pharmacist
and when a trust relationship already existed.
In some situations, pharmacists refrained from proposing the MR
service to patients with whom they had limited communication due to
language differences, psychological troubles or limited intellectual
quotient. Some pharmacists also refrained from proposing the MR ser-
vice if the patient did not come to the pharmacy himself, and when a
third party would need to be involved.
Adoption
Eighty pharmacies decided to participate in the pilot project.
However, 25 pharmacies were considered as drop out because they did
not include any patients (n=20) or did not register interviews in the
web platform (n= 5). Characteristics of participating pharmacies and
pharmacists are presented in Table 2.
Reasons for adopting or rejecting the service
Pharmacists were motivated to integrate this new service in their
practice because they all agreed that this kind of service is an integral
part of the pharmacist's role and is an added-value for the patient. The
pilot project was seen as an opportunity to show their added-value and
change other health care professionals' and patients' attitude about the
profession but also as an opportunity to develop interprofessional
contacts.
Other motivations provided by pharmacists to participate in the
pilot project included the opportunity to review their practice and to
personalize the patient follow up, which created a trust relationship
between the pharmacist and the patient.
There were different reasons for drop outs. First, the lack of time
was evoked by pharmacists as the main barrier to integrate the service
in their practice (n= 13). The heavy workload and the sense of urgency
had led them prioritize other activities. Second, the lack of interest of
patients, and therefore, the difficulty to include patients was mentioned
as a reason for drop out (n=5). Third, five pharmacists declared to
have provided interviews but did not have the time to encode the data
in the web platform. Lastly, three pharmacists started renovation works
in their pharmacies and hence had no possibility to participate. Three
pharmacists did not express any reason.
Implementation
The median time between the official date of the inclusion period of
the study (1st December 2016) and the first patient inclusion by the
pharmacy was 41 days [18–74]. According to the web survey, 42
pharmacies included in total 457 patients. In the web platform, 441 first
interviews and 391 s interviews were registered by 55 pharmacies (re-
presenting on average 8 patients per pharmacy, which is lower than the
12 patients requested for the impact study). The interval between the
first and the second interview was 42 days [4–98]. During the first
interview, 1088 DRPs were recorded by pharmacists and at least one
intervention was proposed for 1054 DRPs (preliminary data, analysis
will follow in the article related to effectiveness of the service).
According to the pharmacists, patients responded positively to the
MR service. The median patient responsiveness score was 3.5 out of 5
[IQR=3.25–3.75], showing a higher score for participation (3.7
[3.4–3.9]) than for enthusiasm (3 [2.7–3.7]), which was mainly due to
the low score for the item “patients request the service” (Appendix 1).
Internal organization and adaptations of the service process
Eight interviewed pharmacists used organizational strategies by
integrating the entire team in the project, adjusting the human resource
staffing during scheduled interview days or planning interview days for
which more staff were available in the pharmacy. Pharmacists working
alone in their pharmacy or pharmacists who did not acquire the support
of their team, prepared and organized interviews after official opening
hours of the pharmacy. On the other hand, some pharmacists preferred
to prepare interviews at home to avoid being disturbed, but conducted
interviews with patients during the pharmacy working hours.
The service process was adapted by pharmacists depending on the
detected DRPs and the need to contact the physician. Some pharmacists
already prepared the treatment plan and directly provided it at the end
of the first interview, which can explain the difference between the
number of first (n= 441) and second interviews (n= 391) delivered.
Some pharmacists found the inclusion criteria related to age was too
restrictive and included younger patients outside of this study.
Pharmacists found it difficult to adhere to the protocol requirement
of having a set inclusion day. Some pharmacists fully respected this
Table 2
Characteristics of pharmacies and pharmacists participating in the pilot project.
Pharmacies' characteristics
Participating pharmacies (n) 80
Pharmacy language
French pharmacies (%) 45.0%
Dutch pharmacies (%) 55.0%
Number of full-time equivalent in the pharmacy
Pharmacists (median [IQR]) 2 [1.2–3]
Technicians (median [IQR]) 1 [0–2]
Pharmacists' characteristics
Participating pharmacists (web survey) (n) 67
Status
Associated pharmacist (%) 38.8%
Manager pharmacist (%) 61.2%




Number of years of experience in pharmacy (median [IQR]) 14 [7–20]
Previous experience with MR (trainings, participation in
awareness campaign or in a previous study) (%)
73.1%
Note: IQR= interquartile range.
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requirement whereas most had difficulties to include all patients who
visited the pharmacy during the defined days. Reasons expressed by
pharmacists were “too many people at the counter” as well as the other
reasons that refrained them to propose the MR service, as previously
explained.
Time needed for the service
The preparation of the first interview took between 30min and 2 h
depending on the number of chronic medicines. This time decreased
with the pharmacist's experience acquired during the project. After
some interviews, pharmacists were more comfortable with the tools and
acquired a systematic method to prepare for the interviews. However,
they considered that 30min was the minimum time required.
The first interviews lasted between 20min and 1 h, with a maximum
of 2 h for some patients. The second interview, including the treatment
plan delivery and the presentation of the proposed interventions, was
shorter and took approximately 10–20min. Finally, the follow-up in-
terview lasted less than 5min and was provided at the counter or by
phone.
Barriers and facilitators
The biggest barrier for all pharmacists was the lack of time con-
sidering the heavy workload and the administrative burden of the
pharmacy. This barrier was related to lack of staff directly related to
lack of remuneration for this kind of service.
The lack of team adoption hindered some pharmacists to provide
the service during opening hours.
The inadequate layout of the pharmacy and the lack of clinical in-
formation about the patient were less frequently expressed by phar-
macists.
On the contrary, a large pharmacy team and the involvement of a
motivated team in the project with an appropriate pharmacy layout/
organization facilitated the implementation of the pilot project in some
pharmacies.
Necessity of educational program and extra training needed
Pharmacists who participated to the workshop stated that it was
useful to understand how to conduct a MR. The role playing performed
by the organizers gave them ideas to introduce the project to patients
and conduct interviews. Available online tools (interview guide and
interaction detection tools) were also described as useful for pharma-
cists and helped them to provide the service.
However, the training needs depended on the personal experiences
and knowledges of pharmacists. Some pharmacists expressed a need to
have trainings about pharmacotherapy whereas others would prefer
more extensive trainings about communication with patients and/or
other health care professionals with interactive role playing.
Surprisingly, some pharmacists expressed needs for trainings that were
already available, such as a coach to help them in practice at the
pharmacy or an e-learning platform.
Interprofessional contact
The contact with the patient's physician varied from one pharmacist
to another. Most of the interviewed pharmacists had positive contacts
with physicians but stated to have easier contact with younger physi-
cians. Some pharmacists, who had previous negative experiences with
physicians, were not at ease and did not contact the physician at all.
Contacting the physician is delicate for pharmacists. They often had
a lot of apprehension before contacting the physician and prepared
their communication thoroughly.
However, once a positive relationship was established, the phar-
macist felt more respected by the physician. This new relationship also
facilitated the collaboration between the pharmacist and the physician
for other patients. As an example, one physician contacted a pharmacist
again for information about a drug-drug interaction for another patient.
Intent of maintenance
According to the online survey, 41.8% of pharmacists thought that
the MR service was feasible in practice and 50.7% thought that it was
feasible but will require some adaptations and additional support for a
large-scale implementation. Only 4.5% thought that the service was not
applicable in practice (3.0% of pharmacists did not provide an answer).
Pharmacists' were concerned about the time and training staff needed
to deliver the service, remuneration, the administrative burden and the
collaboration required with the patients’ physicians.
Satisfaction of pharmacists
Interviewed pharmacists were satisfied with the new MR service
describing it as a professionally satisfying activity. For them, it was a
stimulating, enriching and instructive project.
According to the interviewed pharmacists, included patients were
also happy with the service and were open to the proposed interven-
tions. However, even though pharmacists stated that the utility of the
service was undeniable for patients, some pharmacists thought that the
positive effect of the intervention decreased over time and that they
needed to regularly repeat information to some patients. Therefore,
they concluded that this service could be useful only if it is repeated
over time.
Prospects and long-term support needed
Some pharmacists faced more barriers than they expected. For
them, the service could be feasible in practice but requires adaptations.
First, a broad-based media campaign for patients and physicians was
seen as needed to increase awareness about the pharmacist's role, which
would subsequently help them to propose the service and increase
reach.
Second, reorganization of the internal workload was considered
essential. According to the pharmacists, such reorganization would
require resources such as additional staff and, therefore, requires a
more appropriate remuneration system. Considering the current bud-
getary restriction at the national level, pharmacists thought that the
remuneration of this kind of service would be complicated, which could
hinder the future development of the pharmacist's role.
Lastly, adapted software could help pharmacists save time. The in-
clusion of tools and functionalities of the web platform into the phar-
macy software would avoid transcribing patient information, save time
preparing the first interview and generating the treatment plan.
Moreover, an integrated platform in the software could support internal
communication within the pharmacy team (pharmacy team informa-
tion-sharing).
Discussion
The majority of the participating pharmacists were motivated to
participate in this pilot project and considered the MR service as im-
plementable in practice. However, the implementation was not without
difficulties. The patient inclusion step was challenging for pharmacists,
who experienced on average 50% refusal rates. While some pharmacists
reconsidered the way they proposed the service, other discouraged
pharmacists abandoned the project. Patients' refusal seems to suggest a
lack of awareness of the pharmacist's role. A recent realistic review
highlighted that patients are not aware about pharmacist services and
do not know what kind of care may be expected. However, patients who
understand pharmacy services or received one in the past are more
likely to accept such a service.24 In addition in this study, some patients,
and some pharmacists, were reluctant due to the potential reaction of
the physician. Some physicians did clearly show negative reactions with
the proposed service. The interprofessional collaboration was variable,
and contacts were still delicate for pharmacists. However, most of the
pharmacists experienced positive collaboration with physicians and
stated that younger physicians generally appeared to be more open to
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the service, which is encouraging for the future. One hypothesis is that
recently developed interprofessional workshops taught throughout
university education are starting to change the physicians' attitudes
regarding the pharmacist's role. As proposed by Rubio-Valera et al., the
development of interprofessional workshops could be investigated in
collaboration with the different health care associations to give phar-
macists and physicians the opportunity to meet face-to-face and to
discuss shared objectives.25 In Belgium, meetings between pharmacists
and physicians started to be organized concerning the prescribing be-
haviour (“Concertation medico-pharmaceutique”) but – so far - do not
concern new pharmaceutical services.26 In addition, interviewed
pharmacists suggested the development of broad-based media cam-
paigns to increase the adoption of the service by other health care
professionals and increase patients' awareness of the pharmacists' role.
Lack of time was an important barrier for most of the pharmacists.
In this study, pharmacists explained that the lack of time, due to an
intensive workload and the administrative burden, was directly related
to a lack of staff, and therefore, the lack of remuneration could hinder
pharmacists to employ more staff. Smaller participating pharmacies
showed a lot of motivation in providing the service outside of official
hours, but the pharmacists’ capacity to deliver the service was more
limited as they worked alone, which could hinder long-term im-
plementation. As such, the first strategy suggested by interviewed
pharmacists to overcome this barrier was to adapt the remuneration
system and have it approved at the political level. For pharmacists, an
adapted remuneration means that the time spent to deliver the service
should be taken into account in the financial compensation (1.5–2 h per
patient for a MR). For Noain et al., the implementation cost at the
pharmacy level is represented at 75–95% of the time spent to deliver
the service, followed by the initial implementation cost and finally the
maintenance cost.27 In this pilot project, pharmacists had received 60
euros per included patient, which was perceived as too low by phar-
macists considering the time spent per patient (1.5–2 h). Moreover,
they received it at the end of the study which could explain why re-
muneration was evoked as a barrier during focus groups. According to
Houle et al., time-dependent fees were reimbursed at $93.60 per hour
on average across the world, representing 60 euros per hour.17
Remuneration alone is not sufficient to implement a new service in
practice.28 Pharmacists also mentioned that the reorganization of the
internal workload facilitated the integration in the routine activity but
was partly hindered by the lack of adoption of the service by some staff
members. Kaae et al. showed that the lack of adoption by some phar-
macists, called the ‘laggards’ in accordance with Roger's theory,29 was
more due to a lack of self-efficacy than to a real lack of competencies.
Both individual (e.g. offer individual trainings to laggards to recruit
patients and provide the service) and collective (e.g. feedback, meetings
between staff members) activities were described to overcome this
barrier.12 In this Belgian study, large pharmacies in which the project
was conducted by the pharmacy owner were more proactive in im-
plementing the service, integrating organizational strategies, and in-
tegrating the entire team in the project. Literature also propose a better
integration of pharmacy technicians so that pharmacists could better
focus on their clinical tasks.30,31 Internal strategies, including the re-
organization of the internal workload, were not straightforward for all
pharmacists. Latif et al. suggested that the existing work obligations
should be taken into account and that the organizational culture of the
pharmacy (norms, values, and basic assumptions of a given organiza-
tion including organizational direction) should be understood to pro-
vide adequate resourcing.9,32 Additional trainings, e-learning or mate-
rials on how to integrate a new service in practice could be developed
by postgraduate educational organizations or professional pharmacy
associations to support pharmacists.
Another strategy to save time described by pharmacists is the de-
velopment of an adapted pharmacy software integrating all available
tools for the service (e.g. web platform, DRPs detection tool). In addi-
tion, software could help pharmacists detect eligible patients, remind
the pharmacist, or calculate medication adherence automatically based
on the medical history. Well-designed software could also facilitate
internal communication between staff members on important patient
information received at each visit and ensure a good follow up for
patients. However, such a development requires collaboration between
software developers, professional associations and researchers. With
the same idea, pharmacists proposed to develop a common web-plat-
form to facilitate the exchange of information between pharmacists and
physicians and therefore overcome the lack of clinical data. In Belgium,
an e-health plan is currently in development at the government level to
facilitate information exchange between health care professionals but is
not yet fully implemented.33
For this project, the training workshop was not followed by all
participating pharmacists, but they were all informed about available
resources by email. The training needs varied between pharmacists, and
surprisingly, some pharmacists asked for resources that were already
available, such as e-learning and coaches. These results indicate a less
than optimal use of available resources that could be due to a lack of
clear communication by pharmacists’ associations, a lack of interest of
pharmacists at the beginning of the pilot project, or a lack of antici-
pation from pharmacists regarding the implementation challenge.
During the study, some pharmacists adapted the MR service to fit
with the needs of their patients and with their practice. As an example,
one pharmacist gave the treatment plan at the end of the first interview
and did not conduct a second interview if no DRP was detected and if
the treatment plan did not require adaptation. This method allowed the
pharmacist to satisfy the patient with a direct feedback and to save time
for other patients or other activities. Adaptation is necessary for im-
plementation and intervention flexibility is part of many implementa-
tion models. As long as the core parts of the service were kept, effec-
tiveness should be maintained, but allows for integration into the
unique context of each pharmacy.34
Finally, the development of a new service in the future political
vision is important for its implementation on a larger scale and the
service's maintenance on the long term.35 In Belgium, the development
of the MR service is part of the future political vision for community
pharmacists. Discussion between pharmacist associations and policy
makers resulted in March 2017 in a multiannual framework that
grouped different political initiatives and defined a development path
for community pharmacists.36 This framework plans to progressively
reform the remuneration of pharmaceutical care and to integrate the
concept of the reference pharmacist. The latter was formally im-
plemented in October 2017. With this new concept, the patient can
select his reference pharmacist who has to register all provided drugs
and health products in the patient pharmaceutical record and provide a
validated treatment plan. The reference pharmacist has to contact (if
necessary) other health care professionals who have a therapeutic link
with the patient and to transfer them the validated treatment plan.36
However, policy makers and associations should be aware that moving
from a vision to legislation without an intermediate implementation
stage of building capacity is not sufficient in practice.5,37 In 2017,
Seaton published a call for action for professional organizations to
support pharmacists using dissemination and implementation sci-
ence.38 In this pilot project, professional associations and researchers
worked together to explore the MR service as a next step for the re-
ference pharmacist.
Strengths and limitations
This study was part of a pilot project aiming to implement the MR
service in Belgian community pharmacies and is the first study in-
vestigating the implementation of a potential new MR service in
Belgium. This approach is in full accordance with the new consensus to
determine the needed strategies, according to the encountered barriers
and facilitators, before implementation on a larger scale. This corre-
sponds to the testing stage in the FISpH framework (Fig. 1).9,39
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Both French and Dutch-speaking pharmacists were included in this
pilot project from different regions. Moreover, a variety of methods
were used to gather both quantitative data as well as insights in the
facilitators and barriers for implementation. However, this was a pilot
project which included the voluntary participation of the possibly
higher motivated pharmacists and was therefore not representative of
all Belgian pharmacists. Although drop out pharmacists were also in-
terviewed, opinions of pharmacists who did not participate in the
project were not collected. This implementation evaluation did not
integrate the vision of physicians and patients. Patient satisfaction was
however evaluated in the SIMENON study conducted by the research
team of KU Leuven.19 Concerning patient inclusion, the limitation of 12
inclusions per site may have overestimated the average duration of
medication review as due to learning effect, time to complete a MR
reduced with practice. However, there were no substantial impact of
not achieving the 12 patients per site for the implementation study.
Finally, further studies should evaluate the implementation progress
and monitor implementation outcomes to provide suitable strategies
over time regarding encountered barriers across different im-
plementation stages and levels.
Conclusions
The MR service was implemented in 68% of participating pilot
Belgian community pharmacies but would require adapted resources
and supports for larger scale implementation. The development of some
strategies is currently in progress in Belgium at the political level, such
as the development of a more advanced legal basis to reinforce the role
of the pharmacist, the future revision of the remuneration system for
pharmaceutical care and an e-health platform. However, other strate-
gies, such as continuous support (including interprofessional work-
shops, additional trainings and materials on how to integrate a new
service in practice, local coaches and adapted software), should be
considered and tested to ensure a successful implementation. The en-
gagement of universities, professional associations, policy makers and
health care professionals will be essential for the future development of
this service and its implementation in practice.
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Appendix 1
Themes developed during the qualitative analyses and associated sentences
Re-AIM Outcomes Themes Sentences
Reach Reasons for refusal
according to
pharmacists
Patient do not need the service and were
sufficiently autonomous to manage their
treatment
“I explained [the service] to him and he said « no » nearly
offended because he said « I absolutely do not need this, I
was told once and I am sure to do well. You should rather
talk to people who are bedridden at home and who do not
know anything, who lose their head»” [Ph6]
Patients, or family members, were not used
to this kind of service - intrusion
“There I received a very clear refusal from the family
saying « No, you don't need to intervene, we take care of our
mom »” [Ph3]
“I think that it is also a refusal because they are not used
to… they are a little bit surprised that we ask that to them,
they don't know about what they might be getting into. So,
without knowing, they are suspicious” [Ph20]
Concerns regarding the physician “Many told me « yes, I will talk to my physician » and there
is not a physician who supported the idea” [Ph17]
“One patient was quite particular, she made an appointment
and then she came back by saying us « I read that [patient
consent form], no way! Do not mess my physician with it »”
[Ph19]
“I had a dozen of patients that told me « It is the doctor who
takes care of it and everything is fine, I don't need anything
else »” [Ph22]
Complex patients difficult to include “People who need it most are the ones that are the least easy
to convince” [Ph14]
“We sense when things can be improved or facilitated and
patients were reluctant, not wanting us to get involved in
their fragility” [Ph22]
(continued on next page)
M. Lelubre et al. Research in Social and Administrative Pharmacy 15 (2019) 710–723
718
Appendix 1 (continued)
Re-AIM Outcomes Themes Sentences
MR proposal and reach
of the target population
Pharmacists reconsidered how best to
propose the program over time depending
on patients' reactions
“I got a lot of refusals and I thought it was my fault because
I did not find the right words, and then I thought a little bit
about how I could do it. In fact, I first talked about the
project and then I talk about the benefits for themselves and
then there was almost no refusal” [Ph1]
“They like it, when it is a university project … they are
happy to participate, they feel useful” [Ph2]
“me, it scared them… as soon as I spoke of project, they
were afraid that there was an intrusion into their life” [Ph3]
Easier inclusion of well-known patients –
trust relationship
“I think that knowing the patient well for several years is
something good … it is much better received when we know
the patient well” [Ph18]
Refrained proposals “The language barrier, it is true that patients who did
understand neither French nor English, no need even to try”
[Ph17]
“Someone who lives on the edge of psychiatry…. I am not
ready for this kind of conversation…I think it wouldn't work
out” [Ph16]
“It is the son or daughter that comes, so we know already
that we will need to go at home and that a third person
needs to be there” [Ph22]
Adoption Reasons for adopting or
rejecting the service
Integral part of the pharmacist's role "It is really our job, it is why we are in the pharmacy” [Ph4]
"I think it is really the pharmacist's job, it is to follow
patients, to review their medication" [Ph6]
Added-value for the patient "It offers an added value in the care that you can offer as a
pharmacist to the patient" [Ph13]
"I think that is going to allow to learn [to patients] more
about medication use, the role of each medicine, for which
pathology" [Ph17]
Opportunity to show the pharmacist's
added-value
“yes and the nurse too because they know much more than
us about what is happening in patients' life … it was an
opportunity to advance our profession a little, to change
people's attitude about our profession” [Ph3]
“It is interesting to enhance the value of our profession”
[Ph20]
Opportunity to review their practice “It also allowed us to question ourselves enormously” [Ph1]
Create a trust relationship between the
pharmacist and the patient
“I really like this kind of personalized follow up … the
patient will have more confidence in the pharmacist who
helped him and will be better able to ask more questions, to
come back to the pharmacist” [Ph18]
Opportunity to develop interprofessional
contacts
“It was an opportunity to open the discussion with the
physician” [Ph2]
Implementation Internal organization
and adaptations to the
service process
Organizational strategies “We did a retro-planning, we had first adapted the work
schedule to the pharmacy in order to have more people
present [pharmacists and technicians] some days … so we
decided that we will do the interviews that week, we will
take 3 interviews every day … we had chosen two half-days
to propose to patients to include them in the project, it was
not necessary, in one half-day we had filled the calendar”
[Ph19]
Preparation and organization of interviews
after official opening hours
"It is clearly after official hours that I did this project" [Ph3]
“I confess to have prepared interviews after official hours …
I did all my interviews during the day, when there were
other people who can serve at the counter” [Ph5]
Treatment plan directly provided at the end
of the first interview
“I provided the treatment plan at the end of the first
interview because, considering that we had discussed the
pathologies, the dosages, I said to them «Would you like me
to summarize everything on a treatment plan? » I took
advantage as it was all fresh” [Ph9]
Inclusion of younger patients “I did other interviews but with patients who did not meet
the inclusion criteria, younger people. In general, I find
(continued on next page)
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Appendix 1 (continued)
Re-AIM Outcomes Themes Sentences
younger people much more receptive, people of 45 to 50
years who are polymedicated and have a lot of benzo's”
[Ph3]
Difficulties to adhere to the protocol
requirement
“It is not easy because there are other things that intervene,
if there are many people in the pharmacy, it was not easy to
do” [Ph3]
“I have a little bit selected … I proposed to a first person and
I told myself I will have to start putting it in place and here it
falls on this lady whom I appreciate and I thought to myself
why not” [Ph18]
Time needed for the
service
Time decreased with the pharmacist's
experience
“The first is always very difficult, the second is better and
the third, we already know the tools and it is much easier”
[Ph1]
“Over time, a routine takes place … we do it, we get




Lack of time (heavy workload and
administrative burden) related to lack of
staff
“It is difficult to find a balance between family life and
work. The financial side also because yes, indeed, if we
could have more staff, it might be a little easier” [Ph3]
“It is not easy in the daily practice to say I will take half an
hour and sometimes, I have to adapt my days” [Ph18]
Lack of team adoption “It is true that when you feel less supported by the owner,
you sometimes dare less … finally I dared not say “I'm
leaving half an hour” so I was doing my research on noon
time, it was evening, during the weekend, so all this is really
consuming” [Ph17]
Inadequate pharmacy layout “I think there are very few pharmacies where there really is
a confidential space” [Ph17]
Lack of clinical information “We do not have enough access to the patient's record,
everything about liver failure, kidney failure and that is a





Useful workshop and tools “Tools were useful” [Ph5]
“I found that they were very interesting [workshop] even for
everyday practice, seeing how to motivate, talking with
colleagues, I found it very interesting” [Ph17]
“The workshop, I found it very good, it indicated direction
on how to approach things etcetera” [Ph19]
Interprofessional
contact
Interprofessional contact varied from one
pharmacist to another - Easier contact with
younger physicians
“I had spoken about the project to the physicians before
talking to patients and the approach was very positive…
finally, physicians were more demanding than patients …
However, other physicians, they feel like if we stole their
patients or their job … it is easier with younger
[physicians], they are more demanding” [Ph3]
“I have been cooled by my first contact with a physician
with whom I get along well and he completely dismantled
me … so I figured how will I act for others and then I sent
emails” [Ph9]
“My colleague works a lot with younger physicians and she
tells me that younger physicians, they are different, they
understand that we need to work together” [Ph17]
Apprehension before contacting the
physician
“I need to reflect a lot, depending on each physician, while I
have very good contacts with them but I would be afraid to
spoil it… somewhere yes, it is easy with the study because
here we have the shield “we made a study” so I thought I
was going to put forward it to help” [Ph6]
“It is necessary to use psychology every time and even in
doing this, sometimes it is « I still know what I do! »” [Ph8]
If positive contact → pharmacist felt more
respected
“I have the impression that they respect us more as well.
Now, I know almost all the physicians because I phone
regularly when there are drug-drug interactions, so they are
used having me on the phone for these stuff” [Ph1]
(continued on next page)
M. Lelubre et al. Research in Social and Administrative Pharmacy 15 (2019) 710–723
720
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Re-AIM Outcomes Themes Sentences
New relationship that facilitated the
collaboration between the pharmacist and
the physician for other patients
“Since I have spoken about this, I have a physician who
calls me from time to time asking me « Could you look if I







Stimulating, enriching and instructive
project
“I find it beneficial for practice, it is stimulating” [Ph3]
“The personal development, because I'm less tired of such a
working day even if we had to intercalate sometimes
someone on noon times, it is less sterile, it is exciting” [Ph6]
“I found it very interesting because you learn a lot” [Ph11]
Intervention effectiveness decreased over
time - need to regularly repeat information
to some patients
“I think that we think it has huge impact but if we have a
feedback [from patients] in 6 months, the impact will
already diminish” [Ph1]
“I think it is good to review that again annually” [Ph14]




Increase awareness about the pharmacist's
role
“I think a communication [is needed] that not only comes
from the pharmacist's side” [Ph3]
“I believe that there is information to give to physicians to
prove to them that the pharmacist can bring something to
them” [Ph20]
Reorganization of the internal workload
that require resources
“We do not manage our time very well or have not yet found
the right organization … it requires staff, it takes one person
more” [Ph1]
“I will continue to provide it, to propose if I see that the
patient is demanding … I think it is really good that the
pharmacist takes up his role, but it is true that waiting for a
remuneration from the National Institute for Health and
Disability Insurance, unfortunately, I think they will never
have the budget” [Ph17]
“Very interesting, rewarding for the pharmacist but
unprofitable. I cannot imagine being able to do this without
hiring a person” [Ph20]
Adapted software “If the software could already put all the drugs itself [in the
medication scheme], show the interactions … I'm the one
who manages this project and I think the software must
adapt because there will be changes [for the patient] but if it
is another pharmacist, if there is a change in staff [the
software must inform the pharmacist]” [Ph1]
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3 Through other people (e.g. patients' family, friends) I am aware that

















4 Patients provide information about all the medicines they use (e.g.
medicine cabinet, list of medications).
0 8.6% (5) 48.3% (28) 37.9%
(22)
5.2% (3) 3 [3–4]
5 Patients actively participate during meetings with the pharmacist. 0 5.2% (3) 18.9% (11) 75.9%
(44)
0 4 [4-4]
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7 Patients comply with the interventions proposed by the pharmacist. 0 1.7% (1) 12.1% (7) 86.2%
(50)
0 4 [4-4]
8 When interventions are directed towards modifying a medication plan
(change in medication, dose, schedule etc.), patients adhere to them.
0 1.7% (1) 32.8% (19) 65.5%
(38)
0 4 [3–4]
9 When education is provided (e.g. use of medications, adherence, non-
pharmacological advice etc.), patients adhere to the interventions.
0 1.7% (1) 17.2% (10) 81.1%
(47)
0 4 [4-4]
10 Patients go to the doctor when referred by the pharmacist. 0 1.7% (1) 17.2% (10) 81.1%
(47)
0 4 [4-4]




3.5% (2) 8.6% (5) 86.2%
(50)
0 4 [4-4]
12 Patients keep the pharmacist informed of any changes in their
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